ICD-10 Code C50.412: Left Breast Upper-Outer Quadrant Malignancy

Key Takeaways

C50.412 is the ICD-10-CM code for malignant neoplasm of the upper-outer quadrant of the left female breast.

It is a billable, Female Dx-only code valid from FY2016 through FY2026 under ICD-10-CM Chapter 2 (Neoplasms).

ICD-10-CM instructional notes require an additional Z17.- code to identify estrogen receptor and hormone receptor status.

Pabau’s claims management software helps oncology and women’s health billing teams apply accurate ICD-10 codes and reduce claim denials.

Breast cancer claims are among the most denial-prone in oncology billing. The upper-outer quadrant is the most common anatomical site for female breast malignancies, and incorrect laterality or quadrant specificity on a claim can trigger a rejection before a clinician ever sees the explanation of benefits. ICD-10 Code C50.412 exists precisely to eliminate that ambiguity, capturing left-side, upper-outer quadrant breast cancer with the anatomical precision payers require. Understanding what this code covers, when to use it instead of C50.411 or C50.419, and what additional codes must accompany it separates accurate oncology billing from costly rework.

This reference covers the clinical definition, billable status, laterality and quadrant hierarchy, MS-DRG groupings, receptor status add-on coding, and documentation requirements for C50.412. It also addresses the most common coding errors that lead to denials and audit exposure in breast cancer claims.

ICD-10 Code C50.412: Definition and Clinical Description

ICD-10 Code C50.412 carries the official descriptor: Malignant neoplasm of upper-outer quadrant of left female breast. It sits within ICD-10-CM Chapter 2 (Neoplasms, C00-D49), under the subcategory C50 (Malignant neoplasms of breast). The code was introduced in FY2016 and remains valid through the FY2026 code set, as confirmed by CMS ICD-10-CM annual updates.

The upper-outer quadrant represents the lateral half of the breast above the horizontal midline. Epidemiologically, this quadrant accounts for roughly half of all breast malignancies, making C50.412 one of the most frequently assigned codes in oncology claims workflows. Laterality is encoded directly in the sixth character: “1” for right breast, “2” for left breast, and “9” for unspecified.

Code Hierarchy and Classification Path

The full classification path from general to specific runs as follows:

• Chapter 2: Neoplasms (C00-D49)
• Block C50-C50: Malignant neoplasms of breast
• Category C50: Malignant neoplasm of breast
• Subcategory C50.4: Malignant neoplasm of upper-outer quadrant of breast
• C50.41: Malignant neoplasm of upper-outer quadrant of female breast
• C50.412: Malignant neoplasm of upper-outer quadrant of left female breast

Because ICD-10-CM requires the highest level of specificity available, coders must use C50.412 (not the parent C50.41 or the category C50) whenever the breast is identified as left-sided and the anatomical site is confirmed as the upper-outer quadrant. Failure to use the most specific code available is a documentation deficiency under HIPAA transaction standards.

C50.412 is classified as a Female Dx code, meaning it is not valid for male patients. The women’s health and OB-GYN practice management context is explicit in the descriptor: “female breast.” Assigning C50.412 to a male patient claim will trigger a sex-conflict edit.

Billable Status and Coding Classification

C50.412 is a billable and specific ICD-10-CM code. It can be used directly on claims to indicate a diagnosis for reimbursement purposes without requiring further subdivision. The code has been billable every fiscal year from FY2016 through FY2026, with no status changes or deactivations in that period.

Practices transitioning from older records or reviewing legacy claims may encounter the ICD-9-CM equivalent. C50.412 maps approximately to ICD-9-CM code 174.4 (Malignant neoplasm of upper-outer quadrant of female breast). This crosswalk is approximate, not exact. The ICD-9 code does not carry the laterality specificity of C50.412 since ICD-9-CM Chapter 2 did not encode left vs. right breast at the same granularity. Any research or audit work involving pre-2015 claims should treat this mapping as a comparison tool only, not a direct equivalence.

For practices managing oncology documentation across multiple payers, structured patient records that carry laterality flags forward into billing workflows reduce the risk of defaulting to the unspecified C50.419 when left-side documentation is available in the chart.

Approximate Synonyms and Inclusion Terms

Several clinical descriptions map to C50.412. When these terms appear in pathology reports, operative notes, or radiology findings, coders should confirm the site and assign C50.412 if left-side upper-outer quadrant is specified:

• Primary malignant neoplasm of left upper outer quadrant of female breast
• Left upper outer quadrant breast cancer
• Malignant tumor of upper-outer quadrant of left breast
• Left breast cancer, upper outer quadrant

These synonyms are inclusion terms under the WHO ICD-10 classification framework and are recognized by the NCHS tabular index. The terminology in pathology reports does not always use the ICD phrasing verbatim. Coders trained in breast cancer anatomy can map clinical language accurately to C50.412 when the descriptor confirms the left side and the upper-outer quadrant.

C50.412 vs. Adjacent Laterality and Quadrant Codes

Laterality and quadrant errors are the most common source of medical necessity denials in breast cancer coding. The C50.41 subcategory contains three codes with identical quadrant anatomy but different laterality assignments. Coders must confirm side from the clinical documentation before selecting any of these codes.

C50.419 (unspecified) is a last resort, not a default. Most payers, including Medicare and Medicaid, apply Medical Likelihood Edits (MLEs) that flag unspecified laterality codes when clinical documentation is available. Using C50.419 when the operative report or pathology note clearly identifies the left breast creates audit risk and may trigger a refund request. Per compliance management best practices, coders should query the treating provider when laterality is genuinely absent from the chart rather than defaulting to the unspecified code.

Quadrant-Level Comparisons Within the Left Breast

Beyond laterality, coders must also confirm which quadrant of the left breast is affected. The C50 category contains separate codes for each anatomical quadrant. The upper-outer quadrant (C50.412) is distinct from:

• C50.312: Malignant neoplasm of lower-inner quadrant of left female breast
• C50.212: Malignant neoplasm of upper-inner quadrant of left female breast
• C50.512: Malignant neoplasm of lower-outer quadrant of left female breast
• C50.612: Malignant neoplasm of axillary tail of left female breast
• C50.812: Malignant neoplasm of overlapping sites of left female breast

When a tumor crosses quadrant boundaries, C50.812 (overlapping sites) applies. When the pathology report identifies a specific quadrant, use the corresponding specific code. Oncology billing teams using dermatology and oncology EMR workflows can configure code rule alerts to prevent quadrant-level misassignment at the point of charge capture.

Staging information does not change the ICD-10-CM code assignment. ICD-10-CM C50 codes do not capture AJCC staging. Stage is documented separately in the clinical record and may be used by registries, but C50.412 remains the correct diagnosis code regardless of whether the patient has Stage I or Stage IV disease.

MS-DRG Groupings for ICD-10 Code C50.412

For inpatient hospital claims, C50.412 groups into the Medicare Severity Diagnosis Related Group (MS-DRG) system under version 43.0 (FY2026). MS-DRG assignment determines the base payment rate for inpatient stays. The specific DRG assigned to a given encounter depends on the presence of complications and comorbidities (CC) or major complications and comorbidities (MCC) documented in the record.

Per the CMS MS-DRG v43.0 grouper tables, breast cancer diagnoses in the C50 category typically group within the MDC 9 (Diseases and Disorders of the Skin, Subcutaneous Tissue, and Breast) DRG family. The exact DRG assignment for any single encounter should be verified through the CMS MS-DRG Grouper tool, as secondary diagnoses, procedures performed, and discharge disposition all influence final grouping.

For outpatient claims billed under the Outpatient Prospective Payment System (OPPS), C50.412 does not directly determine an Ambulatory Payment Classification (APC). The APC is driven by the procedure codes (CPT/HCPCS) rather than the diagnosis code. However, C50.412 functions as the primary diagnosis supporting medical necessity for procedures such as mastectomy, sentinel lymph node biopsy, and chemotherapy administration. Payers may use the diagnosis to apply coverage edits and pre-authorization requirements. Oncology practices should ensure their claims management workflows link the correct ICD-10 code to each procedure at the line level.

Commonly Associated Procedure Codes

C50.412 commonly appears alongside the following CPT code families on outpatient and surgical claims:

• 19301-19307: Mastectomy procedures (partial, simple, modified radical)
• 19281-19285: Placement of breast localization device
• 38500-38542: Lymph node biopsy and excision (sentinel node procedures)
• 96401-96417: Chemotherapy administration
• 77061-77067: Diagnostic mammography
• 19083-19086: Breast biopsy with imaging guidance

Pairing C50.412 with unrelated procedure codes is a common audit trigger. Each procedure on the claim should have a documented clinical rationale connecting it to the confirmed left breast malignancy. AI-assisted clinical documentation tools can help providers generate structured notes that clearly tie each procedure to the confirmed diagnosis, reducing the post-submission query rate from billing staff.

Reduce Breast Cancer Claim Denials with Accurate ICD-10 Coding

Pabau's claims management and digital documentation tools help oncology and women's health practices capture the right diagnosis codes at the point of care, reducing denials and streamlining claim submission.

Book a demo

Receptor Status Add-On Codes and Documentation Requirements

ICD-10-CM instructs coders to assign an additional code from the Z17.- category to identify estrogen receptor and hormone receptor status when reporting breast malignancy codes, including C50.412. This is an official instructional note appearing in the ICD-10-CM tabular list at the C50 category level. It is not universally mandated by all payers, but it reflects best-practice coding aligned with CDC/NCHS ICD-10-CM guidelines and the AHA Coding Clinic.

Z17.- Receptor Status Codes

The Z17 category covers estrogen receptor status and related hormone receptor findings. The most relevant codes alongside C50.412 are:

• Z17.0: Estrogen receptor positive status [ER+]
• Z17.1: Estrogen receptor negative status [ER-]

Additional hormone receptor status (progesterone receptor, HER2) is documented separately through other Z-code categories as applicable. When reporting Z17.- alongside C50.412, sequence C50.412 as the principal or primary diagnosis and the Z17.- code as a secondary code. The Z17.- code alone cannot stand as a primary diagnosis.

Not every payer accepts or requires Z17.- codes on every claim type. Hospital outpatient claims under OPPS may have different edit logic than professional claims. Coders should verify payer-specific requirements through the applicable coverage determination or local coverage article. When receptor status has not been tested or is unknown at the time of coding, omit the Z17.- code rather than assign an unspecified code without clinical basis. Practices using digital intake and clinical forms can build receptor status fields into oncology intake workflows so that the information is captured before billing rather than chased after submission.

Documentation Requirements for C50.412

Accurate assignment of C50.412 requires supporting documentation that establishes all three elements encoded in the code: the malignant nature, the anatomical site (upper-outer quadrant), and the laterality (left). Documentation that supports each element typically includes:

• Malignancy confirmation: Pathology report with histological diagnosis of malignant neoplasm; biopsy results; or treating physician’s documented clinical impression supported by imaging
• Quadrant specificity: Radiology report (mammogram, ultrasound, MRI) identifying upper-outer quadrant; surgical operative report specifying quadrant; pathology specimen description with clock-face or quadrant notation
• Laterality: Any of the above documents explicitly identifying the left breast; operative site confirmation; post-procedure nursing documentation

Under the AHA Coding Clinic guidelines, coders may not infer laterality from imaging alone if the treating physician has not confirmed it in a clinical note or operative report. When the chart contains imaging that clearly identifies the left upper-outer quadrant but no physician attestation, the appropriate step is a clinical query, not assumption. Healthcare teams relying on AI-assisted note generation can include laterality and anatomical site as structured data fields in clinical note templates, reducing the frequency of ambiguous documentation at the outset.

Coding Errors, Audit Risks, and Workflow Guidance

The upper-outer quadrant breast cancer codes carry specific audit patterns that oncology billing managers encounter regularly. Knowing these patterns allows practices to build preventive controls rather than respond to denials after the fact.

Common Coding Errors with C50.412

• Using C50.419 when laterality is documented: The most frequent laterality error. If the chart clearly states “left breast,” C50.419 is incorrect.
• Omitting Z17.- receptor status when known: The instructional note is an ICD-10-CM requirement when receptor status is established. Omitting it when the pathology report includes ER status is a documentation gap, not a billing decision.
• Confusing C50.412 with C50.412 in male records: This code is Female Dx only. Any encounter that generates a sex-conflict edit on C50.412 indicates either a patient record error or a coding error.
• Assigning C50.412 without pathological confirmation: Screening findings, imaging abnormalities, or a “rule out” notation in a note do not support assignment of C50.412. A malignant neoplasm code requires confirmed diagnosis.
• Using parent code C50.41 instead of the specific C50.412: C50.41 is a non-billable header code. Some billing systems will auto-correct to C50.412 or C50.411; others will not. Coders must select the billable specific code.

Practices with high breast cancer claim volumes can use structured ICD-10 coding protocols modeled on similar high-specificity code sets to build consistent workflows. The same principle applies across oncology: the correct code is the most specific code the documentation supports, and the documentation must be reviewed, not assumed.

Sequencing Rules for C50.412

C50.412 functions as the principal diagnosis for encounters where the primary reason for the visit is treatment or evaluation of the left breast malignancy. When a patient presents for chemotherapy administration, radiation therapy, or surgical resection directly related to C50.412, the malignancy code is sequenced as the principal diagnosis. The therapy administration code (Z51.11 for antineoplastic chemotherapy, Z51.12 for antineoplastic immunotherapy) may be sequenced as an additional code depending on the encounter type and payer guidelines.

When the encounter is for a complication of treatment rather than the malignancy itself, the complication code takes the principal diagnosis position and C50.412 is listed as an additional code. Consistent sequencing is a foundational element of oncology revenue cycle management. Teams managing complex breast cancer patient panels benefit from claims management software that enforces code sequencing rules at the point of claim review rather than catching errors post-submission.

Expert Picks

Expert Picks

Managing oncology documentation across multiple sites? Claims Management Software helps oncology billing teams link accurate ICD-10 codes to procedures and reduce claim denials at submission.

Looking for structured clinical note workflows? Echo AI supports AI-assisted clinical documentation that captures anatomical site, laterality, and receptor status as structured data fields.

Need digital forms for oncology intake? Digital Forms enables oncology and women’s health practices to build receptor status and laterality confirmation into patient intake workflows.

Running a dermatology or oncology practice? Dermatology EMR Software from Pabau includes documentation and billing tools tailored for skin and oncology-adjacent specialties.

Conclusion

Laterality and quadrant specificity are the two elements that make or break breast cancer claims. C50.412 is the correct, billable ICD-10-CM code when documentation confirms malignancy in the upper-outer quadrant of the left female breast. Getting it wrong by defaulting to C50.419 or confusing it with C50.411 triggers denials that take weeks to resolve and create compliance exposure if the pattern repeats across a patient panel.

Pabau’s claims management software helps oncology and women’s health practices capture accurate ICD-10 codes at the point of care, validate code sequences before submission, and link receptor status documentation to claim lines automatically. To see how Pabau supports breast cancer billing workflows in practice, book a demo.

Frequently Asked Questions